검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | NK cells + PD- (NK cells + PD-, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy) BOE Technology Group Co., Ltd.·NSCLC (Advanced Non-small Cell Lun… ORR 36% |
|---|---|
Overview Program | NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy |
Overview Company | BOE Technology Group Co., Ltd. |
Overview Modality | CGT |
Overview Target | NSCLC (Advanced Non-small Cell Lung Canc |
Overview Indication | NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Toxicology Major finding | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 36% |
Clinical ORR | 36% |
Clinical Result source | ClinicalTrials.gov NCT03785925 |
Clinical Data Tier / Score | A · 26 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 5월 22일 (52일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | NK cells + PD- (NK cells + PD-, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy) BOE Technology Group Co., Ltd.·NSCLC (Advanced Non-small Cell Lun… ORR 36% |
|---|---|
Overview Program | NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy |
Overview Company | BOE Technology Group Co., Ltd. |
Overview Modality | CGT |
Overview Target | NSCLC (Advanced Non-small Cell Lung Canc |
Overview Indication | NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Toxicology Major finding | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 36% |
Clinical ORR | 36% |
Clinical Result source | ClinicalTrials.gov NCT03785925 |
Clinical Data Tier / Score | A · 26 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 5월 22일 (52일 전 · 갱신 권장) |
추천 비교
추천 비교